| Primary |
| Pneumonia |
31.4% |
| Drug Use For Unknown Indication |
12.6% |
| Sepsis |
9.9% |
| Product Used For Unknown Indication |
6.2% |
| Prophylaxis |
5.4% |
| Hypertension |
5.1% |
| Peritonitis |
3.6% |
| Sedation |
2.9% |
| Infection |
2.8% |
| Pneumonia Aspiration |
2.5% |
| Disseminated Intravascular Coagulation |
2.2% |
| Infection Prophylaxis |
2.0% |
| Pneumonia Bacterial |
2.0% |
| Pyrexia |
2.0% |
| Gastroenteritis |
1.8% |
| Cellulitis |
1.7% |
| Gastritis |
1.6% |
| Pyelonephritis |
1.6% |
| Diabetes Mellitus |
1.4% |
| Postoperative Wound Infection |
1.3% |
|
| Interstitial Lung Disease |
10.4% |
| Renal Impairment |
8.2% |
| White Blood Cell Count Decreased |
7.7% |
| Convulsion |
7.1% |
| Liver Disorder |
6.6% |
| Shock |
6.6% |
| Off Label Use |
5.5% |
| Pyrexia |
5.5% |
| Renal Failure Acute |
5.5% |
| Respiratory Failure |
5.5% |
| Pancytopenia |
4.9% |
| Platelet Count Decreased |
4.9% |
| Hepatic Function Abnormal |
4.4% |
| Sepsis |
3.8% |
| Jaundice |
2.7% |
| Toxic Epidermal Necrolysis |
2.7% |
| Hyponatraemia |
2.2% |
| Pneumonia |
2.2% |
| Acute Respiratory Distress Syndrome |
1.6% |
| Blood Bilirubin Increased |
1.6% |
|
| Secondary |
| Pneumonia |
23.0% |
| Sepsis |
11.3% |
| Drug Use For Unknown Indication |
10.6% |
| Prophylaxis |
5.3% |
| Infection |
5.2% |
| Hypertension |
4.3% |
| Sedation |
4.1% |
| Constipation |
3.6% |
| Wound Complication |
3.6% |
| Peritonitis |
3.4% |
| Disseminated Intravascular Coagulation |
3.2% |
| Pyrexia |
3.0% |
| Convulsion Prophylaxis |
2.8% |
| Febrile Neutropenia |
2.8% |
| Gastritis |
2.8% |
| Cerebral Infarction |
2.7% |
| Fluid Replacement |
2.3% |
| Product Used For Unknown Indication |
2.2% |
| Pneumonia Aspiration |
2.0% |
| Infection Prophylaxis |
1.7% |
|
| Renal Impairment |
13.4% |
| Sepsis |
11.9% |
| White Blood Cell Count Decreased |
7.5% |
| Toxic Epidermal Necrolysis |
6.7% |
| Stevens-johnson Syndrome |
6.0% |
| Interstitial Lung Disease |
5.2% |
| Respiratory Failure |
5.2% |
| Off Label Use |
4.5% |
| Platelet Count Decreased |
4.5% |
| Septic Shock |
4.5% |
| Liver Disorder |
3.7% |
| Thrombocytopenia |
3.7% |
| Acute Respiratory Distress Syndrome |
3.0% |
| Blood Bilirubin Increased |
3.0% |
| Enanthema |
3.0% |
| Hepatic Function Abnormal |
3.0% |
| Pancytopenia |
3.0% |
| Prostate Cancer |
3.0% |
| Superinfection |
3.0% |
| Convulsion |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
42.6% |
| Drug Use For Unknown Indication |
23.0% |
| Infection Prophylaxis |
6.5% |
| Prophylaxis |
5.2% |
| Infection |
2.9% |
| Pneumonia |
2.5% |
| Myelodysplastic Syndrome |
2.1% |
| Hypertension |
2.1% |
| Prophylaxis Against Graft Versus Host Disease |
1.6% |
| Febrile Neutropenia |
1.5% |
| Acute Myeloid Leukaemia |
1.4% |
| Pyrexia |
1.4% |
| Multiple Myeloma |
1.2% |
| Diabetes Mellitus |
1.1% |
| Inflammation |
1.1% |
| Gastrointestinal Haemorrhage |
0.9% |
| Neoplasm Malignant |
0.9% |
| Disseminated Intravascular Coagulation |
0.7% |
| Acute Graft Versus Host Disease |
0.7% |
| Constipation |
0.7% |
|
| Renal Impairment |
11.1% |
| Sepsis |
11.1% |
| White Blood Cell Count Decreased |
10.4% |
| Interstitial Lung Disease |
9.7% |
| White Blood Cell Count Increased |
7.6% |
| Pyrexia |
6.9% |
| Platelet Count Decreased |
6.3% |
| Pneumonia |
4.9% |
| Refractoriness To Platelet Transfusion |
3.5% |
| Septic Shock |
3.5% |
| Thrombotic Microangiopathy |
3.5% |
| Hyponatraemia |
2.8% |
| Pneumonia Aspiration |
2.8% |
| Purulent Discharge |
2.8% |
| Thrombocytopenia |
2.8% |
| Febrile Neutropenia |
2.1% |
| Hyperglycaemia |
2.1% |
| Liver Disorder |
2.1% |
| Shock |
2.1% |
| Tuberculosis |
2.1% |
|
